scispace - formally typeset
B

Bilal Piperdi

Researcher at Merck & Co.

Publications -  125
Citations -  12529

Bilal Piperdi is an academic researcher from Merck & Co.. The author has contributed to research in topics: Pembrolizumab & Lung cancer. The author has an hindex of 32, co-authored 122 publications receiving 9727 citations. Previous affiliations of Bilal Piperdi include University of Texas MD Anderson Cancer Center & University of Maryland Medical Center.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz-Ares, +22 more
- 25 Sep 2018 - 
TL;DR: In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus pac litaxel or nab‐paclitaxel resulted in significantly longer overall survival and progression‐free survival than chemotherapy alone.
Journal ArticleDOI

Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer

Mario E. Lacouture, +7 more
- 10 Mar 2010 - 
TL;DR: The incidence of specific >or= grade 2 skin toxicities during the 6-week skin treatment period was reduced by more than 50% in the pre-emptive group compared with the reactive group, and the pre.emptive skin treatment regimen was well tolerated.
Journal ArticleDOI

Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial

Evan W. Alley, +6 more
- 01 May 2017 - 
TL;DR: Pembrolizumab appears to be well tolerated and might confer anti-tumour activity in patients with PD-L1-positive malignant pleural mesothelioma, and response durability and efficacy in this patient population warrants further investigation.
Journal ArticleDOI

Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study

Patrick A. Ott, +7 more
- 16 Aug 2017 - 
TL;DR: Pembrolizumab demonstrated promising antitumor activity in patients with pretreated, PD-L1-expressing SCLC and was consistent with the known safety profile in other tumor types.